Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neurocentria Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. LAYLA SOROUSH is the busiest examiner, responsible for the 1 pending office action. The current prosecution footprint is minimal, with only 1 pending office action. The involvement of 1 distinct examiner and 1 distinct art unit indicates a single point of interaction with the USPTO, which can lead to a more predictable and streamlined prosecution experience.
Practitioners can focus their efforts on the specific examination patterns of LAYLA SOROUSH within the Biotechnology & Pharmaceuticals field, as there are no other active examiners or art units influencing the portfolio. This centralized structure allows for a deep focus on the technical merits of the 1 pending office action. By understanding the specific standards of the 1 distinct art unit, the applicant can better prepare for potential rejections. Since the entire active portfolio consists of this single matter, the strategy should be entirely focused on meeting the examiner's requirements to achieve a favorable outcome for this biotechnology technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18210515 | Magnesium Threonate Compositions and Uses Thereof | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18210515 | Magnesium Threonate Compositions and Uses Thereof | SOROUSH, LAYLA | 1622 | §103DP | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeurocentria Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla Soroush has the most, with 1 of Neurocentria Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
